Eloxx Pharmaceuticals doses first patients in Phase 2B Exaluren study
Eloxx Pharmaceuticals says it has dosed first patients in its Phase 2B Exact study of exaluren for nonsense mutation Alport syndrome.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.